The emerging role of USP29 in cancer and other diseases

被引:1
|
作者
Zhang, Ru [1 ,2 ]
Cai, Zeqiong [2 ]
Ren, Doudou [2 ]
Kang, Ye [2 ]
Zhang, Qi [3 ]
Lu, Xinlan [1 ,4 ]
Tu, Rongfu [2 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Gastroenterol, Xian, Shaanxi, Peoples R China
[2] Xi An Jiao Tong Univ, Affiliated Hosp 1, Medx Inst, Dept Canc Precis Med, Xian, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Emergency Surg, Wuhan, Peoples R China
[4] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Gastroenterol, Xian 710061, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
cancer; deubiquitination; protein stability; target therapy; USP29; UBIQUITIN; PROTEINS; DEGRADATION; INHIBITORS; DISCOVERY; PATHWAY; SYSTEM;
D O I
10.1002/cbf.3928
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Reversible protein ubiquitination is a key process for maintaining cellular homeostasis. Deubiquitinases, which can cleave ubiquitin from substrate proteins, have been reported to be deeply involved in disease progression ranging from oncology to neurological diseases. The human genome encodes approximately 100 deubiquitinases, most of which are poorly characterized. One of the well-characterized deubiquitases is ubiquitin-specific protease 29 (USP29), which is often upregulated in pathological tissues and plays important roles in the progression of different diseases. Moreover, several studies have shown that deletion of Usp29 in mice does not cause visible growth and developmental defects, indicating that USP29 may be an ideal therapeutic target. In this review, we provide a comprehensive summary of the important roles and regulatory mechanisms of USP29 in cancer and other diseases, which may help us better understand its biological functions and improve future studies to construct suitable USP29-targeted therapy systems. Deubiquitinases are deeply involved in human diseases and targeting them provides new opportunities for patients. Many studies have revealed that deubiquitinase USP29 does not affect normal development, but plays an important role in human diseases, especially cancers. In this review, we first summarize the important roles and mechanisms of USP29 in cancer and other diseases, intending to provide potential implications for both basic science and clinical applications.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Enhancer deregulation in cancer and other diseases
    Herz, Hans-Martin
    BIOESSAYS, 2016, 38 (10) : 1003 - 1015
  • [42] The pseudogenes of eukaryotic translation elongation factors (EEFs): Role in cancer and other human diseases
    Cristiano, Luigi
    GENES & DISEASES, 2022, 9 (04) : 941 - 958
  • [43] Role of Ubiquitin-Specific Peptidase 47 in Cancers and Other Diseases
    Pan, Kailing
    Fu, Junhao
    Xu, Wenxia
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [44] The emerging role of 5-hydroxymethylcytosine in neurodegenerative diseases
    Al-Mahdawi, Sahar
    Virmouni, Sara Anjomani
    Pook, Mark A.
    FRONTIERS IN NEUROSCIENCE, 2014, 8
  • [45] Emerging role of miR-520a in human diseases
    Ahmadi, Mohsen
    Morshedzadeh, Firouzeh
    Ghaderian, Sayyed Mohammad Hossein
    Ghafouri-Fard, Soudeh
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 262
  • [46] Emerging concepts on the role of exosomes in lipid metabolic diseases
    Record, Michel
    Poirot, Marc
    Silvente-Poirot, Sandrine
    BIOCHIMIE, 2014, 96 : 67 - 74
  • [47] Early evidence for the role of TRIM29 in multiple cancer models
    Hatakeyama, Shigetsugu
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2016, 20 (07) : 767 - 770
  • [48] Emerging Role of Circular RNAs in Kidney Diseases in Nephrology
    Ma, Cong
    Luan, Junjun
    Kopp, Jeffrey B.
    Zhou, Hua
    CURRENT DRUG TARGETS, 2022, 23 (04) : 330 - 343
  • [49] The emerging multifaceted role of PINK1 in cancer biology
    Wang, Meng
    Luan, Shijia
    Fan, Xiang
    Wang, Jie
    Huang, Ju
    Gao, Xu
    Han, Dong
    CANCER SCIENCE, 2022, 113 (12) : 4037 - 4047
  • [50] The Emerging Role of TYRO3 as a Therapeutic Target in Cancer
    Smart, Sherri K.
    Vasileiadi, Eleana
    Wang, Xiaodong
    DeRyckere, Deborah
    Graham, Douglas K.
    CANCERS, 2018, 10 (12):